BI-1607 is a humanized monoclonal antibody targeting CD32b/FcgammaRIIB. It acts as an antagonist, capable of blocking the inhibitory effects of FcgammaRIIB on immune effector cells. When used in combination with Trastuzumab, BI-1607 can significantly suppress HER2-positive solid tumors, including advanced gastric cancer (GC).
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
